Literature DB >> 17905631

The ESPOIR cohort: a ten-year follow-up of early arthritis in France: methodology and baseline characteristics of the 813 included patients.

Bernard Combe1, Joëlle Benessiano, Francis Berenbaum, Alain Cantagrel, Jean-Pierre Daurès, Maxime Dougados, Patrice Fardellone, Bruno Fautrel, Réné-Marc Flipo, Philippe Goupille, Francis Guillemin, Xavier Le Loet, Isabelle Logeart, Xavier Mariette, Olvier Meyer, Philippe Ravaud, Nathalie Rincheval, Alain Saraux, Thierry Schaeverbeke, Jean Sibilia.   

Abstract

OBJECTIVES: The French Society of Rheumatology initiated a large national multicenter, longitudinal and prospective cohort, the so-called "ESPOIR cohort study" in order to set up databases to allow various investigations on diagnosis, prognostic markers, epidemiology, pathogenesis and medico-economic factors in the field of early arthritis and rheumatoid arthritis.
METHODS: Patients were recruited if they had undifferentiated arthritis or rheumatoid arthritis, of less than 6 months disease duration and if they were DMARD and steroids naïve. Patients have then to be followed every 6 months during the first 2 years then every year during at least 10 years. Clinical, biological, radiographic and medico-economic databases have been constituted to fit in the different objectives of the project and more than 20 scientific studies have already been accepted by the scientific committee.
RESULTS: 813 patients were included (76.75% were female). The mean age was 48.07+/-12.55 years. The mean delay from the onset of symptoms to referral to the rheumatologist was 74.8+/-76.6 days. Baseline swollen and tender joint counts were 7.19+/-5.37 and 8.43+/-7.01; DAS28 score was 5.11+/-1.31. CRP was abnormal in 38.9% of the patients; 44.2%, 45.8% and 38.8% had respectively IgM rheumatoid factor (RF), IgA RF and anti-CCP antibodies. HLA DRB1*01 or 04 genes were found in 56.7% of them. Finally, 22% of these patients had erosions on hand or feet at baseline.

Entities:  

Mesh:

Year:  2007        PMID: 17905631     DOI: 10.1016/j.jbspin.2007.06.001

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN: 1297-319X            Impact factor:   4.929


  35 in total

1.  The gap between practice and guidelines in the choice of first-line disease modifying antirheumatic drug in early rheumatoid arthritis: results from the ESPOIR cohort.

Authors:  Mathilde Benhamou; Nathalie Rincheval; Carine Roy; Violaine Foltz; Sylvie Rozenberg; Jean Sibilia; Thierry Schaeverbeke; Pierre Bourgeois; Philippe Ravaud; Bruno Fautrel
Journal:  J Rheumatol       Date:  2009-03-13       Impact factor: 4.666

Review 2.  The epidemiology of early inflammatory arthritis.

Authors:  Johanna M W Hazes; Jolanda J Luime
Journal:  Nat Rev Rheumatol       Date:  2011-06-14       Impact factor: 20.543

3.  MR imaging of atlantoaxial joint in early rheumatoid arthritis.

Authors:  N Magarelli; F Simone; R Amelia; A Leone; S Bosello; G D'Antona; A Zoli; G Ferraccioli; L Bonomo
Journal:  Radiol Med       Date:  2010-07-31       Impact factor: 3.469

4.  Profile and course of early rheumatoid arthritis in Morocco: a two-year follow-up study.

Authors:  Karima Benbouazza; Bahia Benchekroun; Hanan Rkain; Bouchra Amine; Fatiha Bzami; Leila Benbrahim; Ouafa Atouf; Malika Essakalli; Redouane Abouqal; Maxime Dougados; Najia Hajjaj-Hassouni
Journal:  BMC Musculoskelet Disord       Date:  2011-11-23       Impact factor: 2.362

5.  Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the community treated with methotrexate or leflunomide: results from the ESPOIR cohort.

Authors:  Bruno Fautrel; Benjamin Granger; Bernard Combe; Alain Saraux; Francis Guillemin; Xavier Le Loet
Journal:  Arthritis Res Ther       Date:  2012-11-19       Impact factor: 5.156

6.  Disease activity score-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis: data from the GUEPARD trial and ESPOIR cohort.

Authors:  M Soubrier; C Lukas; J Sibilia; B Fautrel; F Roux; L Gossec; S Patternotte; M Dougados
Journal:  Ann Rheum Dis       Date:  2011-01-17       Impact factor: 19.103

7.  IL2RA is associated with persistence of rheumatoid arthritis.

Authors:  H W van Steenbergen; J A B van Nies; A Ruyssen-Witrand; T W J Huizinga; Al Cantagrel; F Berenbaum; A H M van der Helm-van Mil
Journal:  Arthritis Res Ther       Date:  2015-09-08       Impact factor: 5.156

8.  Markers of B-lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohort.

Authors:  Jacques-Eric Gottenberg; Corinne Miceli-Richard; Béatrice Ducot; Philippe Goupille; Bernard Combe; Xavier Mariette
Journal:  Arthritis Res Ther       Date:  2009-07-23       Impact factor: 5.156

9.  Validation of ACR/EULAR definition of remission in rheumatoid arthritis from RA practice: the ESPOIR cohort.

Authors:  Bin Zhang; Bernard Combe; Nathalie Rincheval; David T Felson
Journal:  Arthritis Res Ther       Date:  2012-06-29       Impact factor: 5.156

10.  Osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand as prognostic factors in rheumatoid arthritis: results from the ESPOIR cohort.

Authors:  Rachel Audo; Claire Daien; Laura Papon; Cédric Lukas; Olivier Vittecoq; Michael Hahne; Bernard Combe; Jacques Morel
Journal:  Arthritis Res Ther       Date:  2015-07-29       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.